Active Ingredient History
Cemiplimab, sold under the brand name Libtayo, is a monoclonal antibody medication for the treatment of squamous cell skin cancer. Cemiplimab belongs to a class of drugs that binds to the programmed death receptor-1 (PD-1), blocking the PD-1/PD-L1 pathway. Wikipedia
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Adenocarcinoma (Phase 2)
Brain Neoplasms (Phase 2)
Breast Neoplasms (Phase 2)
Carcinoma (Phase 2)
Carcinoma, Basal Cell (Phase 2)
Carcinoma, Hepatocellular (Phase 2)
Carcinoma in Situ (Phase 1)
Carcinoma, Merkel Cell (Phase 2)
Carcinoma, Non-Small-Cell Lung (Phase 3)
Carcinoma, Renal Cell (Phase 1/Phase 2)
Carcinoma, Squamous Cell (Phase 3)
Colonic Neoplasms (Phase 2)
Colorectal Neoplasms (Phase 2)
Diffuse Intrinsic Pontine Glioma (Phase 1/Phase 2)
Endometrial Neoplasms (Phase 1/Phase 2)
Esophageal Neoplasms (Phase 1/Phase 2)
Fallopian Tube Neoplasms (Phase 1/Phase 2)
Glioblastoma (Phase 2)
Glioma (Phase 1/Phase 2)
Hamartoma (Phase 1/Phase 2)
Head and Neck Neoplasms (Phase 2)
Hepatitis B virus (Phase 1/Phase 2)
HIV Infections (Phase 1/Phase 2)
Hodgkin Disease (Phase 2)
Hypopharyngeal Neoplasms (Phase 2)
Kidney Neoplasms (Phase 1/Phase 2)
Laryngeal Neoplasms (Phase 2)
Liposarcoma (Phase 2)
Lung Neoplasms (Phase 2)
Lymphoma (Phase 1/Phase 2)
Lymphoma, Follicular (Phase 1)
Lymphoma, Large B-Cell, Diffuse (Phase 1)
Lymphoma, Mantle-Cell (Phase 1)
Lymphoma, Non-Hodgkin (Phase 1)
Lymphoma, T-Cell (Phase 2)
Melanoma (Phase 3)
Mouth Neoplasms (Phase 2)
Multiple Myeloma (Phase 2)
Mycosis Fungoides (Phase 1/Phase 2)
Neoplasm Metastasis (Phase 2)
Neoplasms (Phase 2)
Oropharyngeal Neoplasms (Phase 2)
Ovarian Neoplasms (Phase 1/Phase 2)
Pancreatic Neoplasms (Phase 2)
Prostatic Neoplasms (Phase 1/Phase 2)
Prostatic Neoplasms, Castration-Resistant (Phase 1/Phase 2)
Sarcoma (Phase 2)
Skin Neoplasms (Phase 2)
Squamous Cell Carcinoma of Head and Neck (Phase 2)
Stomach Neoplasms (Phase 1/Phase 2)
Thyroid Neoplasms (Phase 1/Phase 2)
Triple Negative Breast Neoplasms (Phase 2)
Urinary Bladder Neoplasms (Phase 1/Phase 2)
Uterine Cervical Neoplasms (Phase 3)
Uterine Neoplasms (Phase 1/Phase 2)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue
